BioSpace News Archive

Recent research shows those who had been hospitalized due to COVID-19 might already have a reduced sense of smell and taste, not just for the short term, but possibly for life.

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio, a clinical-stage messenger RNA therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company focused on treating diseases of the eye, announced the company has entered a research collaboration with Children’s Medical Research Institute in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies.

Targovax ASA, a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, announces that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA.

Asieris Pharmaceuticals announced dosing of the first patient in Europe in its multinational, multicenter, Phase III clinical trial of its photodynamic drug-device combination product APL-1702, Cevira® which is being developed for a novel non-surgical treatment of cervical high-grade squamous intraepithelial lesions.

The cooperation between Inventum Genetics and the University of Marburg is a long-term agreement.

Nordic Nanovector ASA announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for stem cell transplantation.

European Wellness Biomedical Group has signed a memorandum of understanding with Li Hua Biotechnology to formalize strategic alliance in scientific research and clinical trials development for fertility and immunology in Hunan, China.

Photocure ASA announces that its partner Asieris Pharmaceuticals has administered the first European patient in its phase III clinical trial for APL-1702.

Algenex SL, a biotech company backed by Cleon Capital and Columbus Ventures delivering disruptive technologies for recombinant biologics production, has taken significant steps towards full commercialisation of its CrisBio® platform through the first recommendation for approval by a global regulator of a biological produced with the system.